NZB/W lupus-prone mice -which develop a disease that closely replicates human systemic lupus erythematosus (SLE), including an elevated type I IFN-driven gene signature -oral administration of the compound once daily for 2 days resulted in decreased levels of canonical type I IFN-regulated genes in a dose-dependent manner. It also provided protection from nephritis.
Finally, BMS-986165 reduced type I IFN-driven responses in vitro in blood from 31 patients with SLE, and blocked the induction of a type I IFN-driven gene signature in healthy volunteers who were given BMS-986165 and then challenged with type I IFN.
BMS-986165 has already shown promise in a phase II study in patients with psoriasis. "Psoriasis is largely an IL-23-driven disease, whereas inflammatory bowel disease and lupus are more heterogeneous with multiple pathways driving disease. The combination of validated mechanisms that TYK2 inhibition provides in an oral agent supports further study of BMS-986165 as a potential future treatment option for multiple immune-mediated diseases, " concludes Burke. In vitro, BMS-986165 showed high selectivity for the TYK2 pseudokinase domain when tested against a panel of 249 kinases and pseudokinases. In primary human peripheral blood mononuclear cells stimulated with IFNα and IL-23, BMS-986165 inhibited TYK2-mediated phosphorylation of STAT1 and STAT3, respectively. By contrast, it was considerably less potent (>100-fold) against receptor-mediated pathways that depended on Janus kinases (JAKs) other than TYK2.
M. Teresa Villanueva
In vivo, prophylactic treatment of mice with BMS-986165 before induction of colitis resulted in complete protection from weight loss, epithelial hyperplasia and damage in the colon. In female 
Enhancing CAR-T cell activity
Using chimeric antigen receptor (CAR)-T cell therapy to treat solid tumours has proved challenging. Ma et al. have now designed a vaccine comprising amphiphile CAR-T ligands (amph-ligands) that associate with albumin at the injection site, traffic to lymph nodes and decorate the surfaces of antigen-presenting cells, to prime CAR-Ts in the lymph node microenvironment. In immunocompetent mouse models, amphligand immunization substantially induced CAR-T expansion, without toxicity. Furthermore, amph-ligands effectively primed tumour antigen-specific CAR-Ts, slowing tumour growth and prolonging survival in syngeneic solid tumour mouse models.
OrIgINAl ArtIclE Ma, L. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162-168 (2019) 
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Applying the human metabolome
Understanding the level of drug-target affinity required to exert therapeutic action is essential for drug discovery. Bofill et al. analysed a set of 815 interactions between 566 drugs and 129 primary targets, associated with 79 endogenous ligands, and found that 71% of drug-target affinities were greater than that of the corresponding endogenous ligand, with 96% being within two orders of magnitude. They propose that the human endogenous metabolome may serve as a baseline for the primary pharmacology of drugs and, using serotonin 5-HT 2B receptor agonism and valvular heart disease risk as an example, show how this knowledge may be applied to assess the risk of safety events associated with the secondary pharmacology of a drug. 
Programming bacteria to fight cancer
The anti-phagocytic receptor CD47 is overexpressed in several cancers and represents an attractive therapeutic target. However, systemic CD47 blockade can result in anaemia and thrombocytopenia. Chowdhury and colleagues engineer an Escherichia coli strain containing a synchronized lysis circuit that colonizes tumours owing to the immunoprivileged tumour microenvironment, and undergoes intratumoural quorum lysis to release an encoded nanobody antagonist of CD47. In mouse syngeneic tumour models, local delivery of engineered bacteria increased tumour-infiltrating T cell activation, stimulated tumour regression, prevented metastasis and increased survival. 
Role of the gut microbiota in PCOS
Polycystic ovary syndrome (PCOS) is associated with infertility and metabolic syndrome, but the mechanisms involved remain poorly understood. Here, Qi et al. find that the abundance of Bacteroides vulgatus is markedly higher in individuals with PCOS compared with healthy controls, which promotes the metabolism of bile acid species that increase intestinal IL-22 production. Transplantation of PCOS faecal microbiota or B. vulgatus into mice disrupted bile acid metabolism, IL-22 production, insulin sensitivity and ovarian function, while IL-22 or bile acid administration to mice with PCOS improved insulin resistance, ovarian dysfunction and infertility.
